<?xml version="1.0" encoding="UTF-8"?>
<p>The activity of CQ has also been indirectly demonstrated against DENV infection. The results obtained by Kleber and colleagues showed that CQ suppressed TNF-α and IFN-γ production, and it was hypothesized that CQ might be used to treat patients suspected of having dengue disease, avoiding the more severe form of dengue hemorrhagic fever and/or shock. A clinical trial was also established to verify the effect of CQ versus placebo in DENV-infected patients in Brazil. CQ promoted a reduction in the intensity of pain and an improvement in the well-being of patients with DENV infection but did not alter the duration of the disease or the intensity and days of fever (
 <xref rid="microorganisms-08-00085-t001" ref-type="table">Table 1</xref>) [
 <xref rid="B36-microorganisms-08-00085" ref-type="bibr">36</xref>].
</p>
